Abstract
Anaplastic Lymphoma Kinase (ALK) fusion is an important driver mutation and therapeutic target. At present, more than 20 fusion partners for ALK in NSCLC have been reported. However, ALK intergenic-breakpoint fusions confound fusion detection and target treatment. Here, we reported a 53-year-old early-stage lung adenocarcinoma patient with an MIR548AD-ALK intergenic fusion and was verified by immunohistochemical staining (IHC). In early-stage NSCLC, compared with other clinically relevant driver mutations, ALK fusions were associated with a trend toward poor disease outcomes. Our Next-generation sequencing (NGS) and IHC results may indicate the prognosis of the patient and provide an alternative treatment option for postoperative recurrence.
This is a preview of subscription content, log in via an institution to check access.
References
Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT, Gainor JF (2018) Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer 122:67–71. https://doi.org/10.1016/j.lungcan.2018.05.020
Li P, Gao Q, Jiang X, Zhan Z, Yan Q, Li Z, Huang C (2019) Comparison of clinicopathological features and prognosis between ALK rearrangements and EGFR mutations in surgically resected early-stage lung adenocarcinoma. J Cancer 10(1):61–71. https://doi.org/10.7150/jca.26947
Li W, Liu Y, Li W, Chen L, Ying J (2020) Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC. J Thora Oncol 15(7):1223–1231. https://doi.org/10.1016/j.jtho.2020.02.023
Lin C, Shi X, Yang S, Zhao J, He Q, Jin Y, Yu X (2019) Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. Lung Cancer 131:62–68. https://doi.org/10.1016/j.lungcan.2019.03.018
Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L (2018) Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol 15:694–708. https://doi.org/10.1038/s41571-018-0081-4
Tian P, Liu Y, Zeng H, Tang Y, Lizaso A, Ye J, Shao L, Li Y (2020) Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. J Cancer Res Clin Oncol 146(4):935–944. https://doi.org/10.1007/s00432-019-03116-6
Zhang J, Zou C, Zhou C, Luo Y, He Q, Sun Y, Zhou J, Ke Z (2020) A Novel Linc00308/D21S2088E intergenic region ALK fusion and its enduring clinical responses to crizotinib. J Thora Oncol 15(6):1073–1077. https://doi.org/10.1016/j.jtho.2020.03.009
Acknowledgement
The authors thank Wanglong Deng, Xueyu Yang and Guanghua Lu for their contributions to the data collection of this research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Dou, Y., Duan, Q., Qi, C. et al. An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma. J Cancer Res Clin Oncol 147, 1865–1867 (2021). https://doi.org/10.1007/s00432-021-03526-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-021-03526-5